RIP140 and LCoR expression in gastrointestinal cancers

Mouna Triki; Dorra Ben Ayed-Guerfali; Ines Saguem; Slim Charfi; Lobna Ayedi; Tahia Sellami-Boudawara; Vincent Cavailles; Raja Mokdad-Gargouri

doi:10.18632/oncotarget.22686

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

RIP140 and LCoR expression in gastrointestinal cancers

Mouna Triki, Dorra Ben Ayed-Guerfali, Ines Saguem, Slim Charfi, Lobna Ayedi, Tahia Sellami-Boudawara, Vincent Cavailles _ and Raja Mokdad-Gargouri

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:111161-111175. https://doi.org/10.18632/oncotarget.22686

Metrics: PDF 1264 views | HTML 2296 views | ?

Abstract

Mouna Triki1,2, Dorra Ben Ayed-Guerfali2, Ines Saguem3, Slim Charfi3, Lobna Ayedi3, Tahia Sellami-Boudawara3, Vincent Cavailles1,* and Raja Mokdad-Gargouri2,*

1IRCM (Institute of Cancer Research of Montpellier), INSERM U1194, Montpellier University, Montpellier, France

2Center of Biotechnology of Sfax, Laboratory of Eukaryotic Molecular Biotechnology, Sfax University, Sfax, Tunisia

3Department of Anatomopathology, Habib Bourguiba Hospital, Sfax, Tunisia

*These authors have to be considered as last co-authors

Correspondence to:

Vincent Cavailles, email: [email protected]

Keywords: gastrointestinal cancer; RIP140; LCoR; immunohistochemistry; patient survival

Received: September 04, 2017 Accepted: November 05, 2017 Published: November 25, 2017

ABSTRACT

The transcription coregulators RIP140 and LCoR are part of a same complex which controls the activity of various transcription factors and cancer cell proliferation. In this study, we have investigated the expression of these two genes in human colorectal and gastric cancers by immunohistochemistry. In both types of tumors, the levels of RIP140 and LCoR appeared highly correlated. Their expression tended to decrease in colorectal cancer as compared to adjacent normal tissues but was found higher in gastric cancer as compared to normal stomach. RIP140 and LCoR expression correlated with TNM and tumor differentiation. Significant correlations were observed with expression levels of key proteins involved in tumor progression and invasion namely E-cadherin and Cyclooxygenase-2. Survival analysis showed that patients with LCoR^low/RIP140^high colorectal tumors have a significant prolonged overall and disease-free survival. In gastric cancer, high LCoR expression was identified as an independent marker of poor prognosis suggesting a key role in this malignancy. Altogether, these results demonstrate that RIP140 and LCoR have a prognostic relevance in gastrointestinal cancers and could represent new potential biomarkers in these tumors.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22686

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

RIP140 and LCoR expression in gastrointestinal cancers

Abstract